Invention Grant
- Patent Title: Use of mGluR5 antagonists for the treatment of gerd
- Patent Title (中): 使用mGluR5拮抗剂治疗黄疸
-
Application No.: US10517869Application Date: 2003-06-19
-
Publication No.: US07964609B2Publication Date: 2011-06-21
- Inventor: Anders Lehmann , Jan Mattsson , Thomas M. Stormann
- Applicant: Anders Lehmann , Jan Mattsson , Thomas M. Stormann
- Applicant Address: SE Sodertalje
- Assignee: AstraZeneca AB
- Current Assignee: AstraZeneca AB
- Current Assignee Address: SE Sodertalje
- Agency: White & Case LLP
- Priority: SE0201943 20020620
- International Application: PCT/US03/16223 WO 20030619
- International Announcement: WO04/000316 WO 20031231
- Main IPC: A61K31/44
- IPC: A61K31/44 ; A61L31/443
Abstract:
The present invention relates to the use of metabotropic glutamate receptor 5 antagonists for the inhibition of transient lower esophageal sphincter relaxations. A further aspect of the invention is directed to the use of metabotropic glutamate receptor 5 antagonists for the treatment of gastroesophageal reflux disease, as well as for the treatment of regurgitation.
Public/Granted literature
- US20060128760A1 Use of mglur5 antagonists for the treatment of gerd Public/Granted day:2006-06-15
Information query
